Status:
COMPLETED
Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Biopsy-confirmed IgA Nephropathy
Proteinuria Less Than 0.5 g Per Day
Eligibility:
All Genders
18-25 years
Phase:
PHASE3
Brief Summary
Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. The treatment of IgA nephropathy with normal renal function and minimal proteinuria is unknown. S...
Eligibility Criteria
Inclusion
- age between 18 and 65
- biopsy-confirmed IgA nephropathy
- proteinuria less than 0.5 g per day, normal blood pressure, and serum creatinine below 120 umol/l
- willingness to give written informed consent and willingness to participate in and comply with the study protocol
Exclusion
- expected survival less than 2 years
- pregnant or nursing mother, or women of childbearing potential without an effective method of birth control
- history of myocardial infarction, congestive heart failure, or any other medical indication that necessitate the use of ACE inhibitor
- evidence of clinically significant hepatic, gastrointestinal, autoimmune disease
- history of malignancy, drug or alcohol abuse
- participation in any previous trial on ACE inhibitor
- taking other investigational drugs within the past 30 days
- history of non-compliance to medical regimens and patients who are considered potentially unreliable
- known history of sensitivity / allergy to ACE inhibitor
Key Trial Info
Start Date :
April 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01225445
Start Date
April 1 2002
End Date
October 1 2010
Last Update
October 21 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine & Therapeutics, Prince of Wales Hospital
Shatin, Hong Kong